Yuandong Biotech (688513.SH): Phase III clinical trial of eugliptin tablets as a single agent to treat type 2 diabetes reached the expected goals

Gelonghui, April 30丨Yuandong Biology (688513.SH) announced that the phase III clinical trial of the self-developed Class 1 new drug eugliptin tablets to treat type 2 diabetes as a single agent has recently obtained a clinical trial summary report and achieved the expected goals. Phase III clinical trial results showed that euglithin tablets can significantly improve glycated hemoglobin (HbA1c), fasting blood sugar, and blood sugar 2 hours after meals in patients with type 2 diabetes who have poor exercise control on a simple diet. Euglitine tablets as a single drug treatment for Chinese type 2 diabetics with poor exercise control on a simple diet can significantly improve patients' glycated hemoglobin, fasting blood sugar, and after meals2

Gelonghui FinanceApr 30 16:11

Yuandong Biotech (688513.SH) plans to launch 2024 employee stock ownership plan

Yuandong Biotech (688513.SH) disclosed the 2024 employee stock ownership plan (draft). The number of participants was no more than 208, and the total amount of capital to be raised was no more than 346.938 million yuan. Using “shares” as the subscription unit, each share was 1 yuan. The maximum number of shares in the employee shareholding plan was 346.938 million shares. The final total amount of capital raised was based on the actual total amount of capital raised. The source of shares in the employee stock ownership plan is Yuandong Biotech's A-share common stock shares in the company's repurchase special securities account. After the employee shareholding plan is reviewed and approved by the company's shareholders' meeting, the company will be obtained through non-transactional transfers and other methods permitted by laws and regulations

Zhitong FinanceApr 28 17:31

Yuandong Biology (688513): A variety of potential new products have been approved, and the internationalization of formulations opens up room for long-term growth

Performance summary: For the full year of 2023, the company achieved operating income of 1,117 million yuan (-4.56%), net profit attributable to mother of 227 million yuan (-8.09%), and net profit not attributable to mother of 158 million yuan (-4.32%)

西部證券Apr 26 00:00

Guojin Securities released a research report on April 24 stating that Yuandong Biotech (688513.SH) was given an increased rating. The main reasons for the rating include: 1) the risk of collection is gradually being clarified, and the anesthesia pipeline

Guojin Securities released a research report on April 24 stating that Yuandong Biotech (688513.SH) was given an increased rating. The main reasons for the rating include: 1) the risk of collection is gradually being clarified, and the anesthesia pipeline is strengthened; 2) the development of high-end formulations and the full internationalization of raw materials. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 24 10:13

Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Adds CN¥461m in Market Cap and Insiders Have a 49% Stake in That Gain

Key Insights Significant insider control over Chengdu Easton Biopharmaceuticals implies vested interests in company growth The top 3 shareholders own 50% of the company Using data from analyst for

Simply Wall StApr 24 06:23

Ping An Securities released a research report on April 23 stating that it gave Yuandong Biology (688513.SH) a recommended rating. The main reasons for the rating include: 1) the company's collection risk is basically clear; 2) the refined hemp specialty i

Ping An Securities released a research report on April 23 stating that it gave Yuandong Biology (688513.SH) a recommended rating. The main reasons for the rating include: 1) the company's collection risk is basically clear; 2) the refined hemp specialty innovation pipeline continues to advance, which is expected to usher in intensive catalysis in the short to medium term; 3) specialty hemp injections go overseas, driving the company's long-term growth. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 23 19:39